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Introduction
Drug metabolising enzymes are highly involved in the metabolism of potentially dangerous foreign chemicals into less harmful and more readily excretable molecules in humans. Among these enzymes, human flavin-containing monooxygenase isoform 3 (hFMO3) is able to catalyse the oxygenation of a variety of xenobiotics with varied chemical structures, including many therapeutic drugs [1] . This enzyme is microsomal, FAD-and NADPH-dependent and, is able to activate molecular oxygen to catalyse substrate oxygenation [1] [2] [3] 4] . Recently, in addition to xenobiotic metabolism, FMO3 has also been implicated in the development of atherosclerosis, cholesterol imbalance and to glucose and lipid metabolism [5] [6] [7] . Human FMO3 activity is widely recognized as being part of the first-pass metabolism of drugs together with the superfamily of cytochrome P450 enzymes [1] . Differently to cytochromes P450, hFMO3 metabolism is responsible for the polarization of drugs and xenobiotic molecules that are consequently converted into more excretable species so hFMO3 activity has clinical relevance in the detoxification and clearance processes. Therefore, the development of new chemical entities that can be metabolized by hFMO3 rather cytochromes P450, can decrease the toxic side effects and be more tolerable by patients. In addition, while cytochromes P450 can be readily induced or inhibited with high probability of adverse drug-drug interactions, hFMO3 activity has not been shown to be influenced by foreign chemical species [1] .
The natural polymorphism of FMO enzymes has been shown to strongly influence interindividual drug response increasing the significance of these enzymes from a pharmacological as well as toxicological point of view [7, 8] . Human FMO3 is a highly polymorphic enzyme and many of its single nucleotide polymorphisms are present at reasonably high frequency within the population [9] . In vivo studies of the metabolism of drugs such as benzydamine, tamoxifen and sulindac sulfide, have demonstrated a strict relationship between some common hFMO3 nucleotide polymorphisms and their altered metabolism. It has also been demonstrated that simultaneous occurrence, like in the case of the two common polymorphic variants E158K and E308G, leads to a significant alteration in hFMO3 metabolism [10] . Furthermore, mutations leading to the total loss of hFMO3 function are the genetic basis for the trimethymaminuria disease [11, 12] . People affected by this disease are not able to metabolize the odorous trimethylamine to its odourless N-oxide and the accumulated trimethylamine leads to the so-called fish-odour syndrome [13] .
For these reasons, the understanding of hFMO3 pharmacogenetics would be fundamental in the prediction of individual drug response and therapy efficacy leading to a major contribution to drug design and development [9] . In light of this, much attention has been concentrated on the development of new methods useful for pharmacological research relevant to hFMO3 catalysis. One such technique which is applicable to these enzymes is electrochemistry where the direct electrochemical response of hFMO3 on gold and carbon surfaces has been previously demonstrated by our group [14] [15] [16] . The advantage of direct immobilization of hFMO3 on electrode surface is mostly related to the possibility of using reducing equivalents provided by the electrode surface instead of those of NADPH which is its natural redox partner, thus improving experimental conditions in terms of costs, reliability and efficiency. To further enhance the electrochemical response of this enzyme novel material such as graphene and/or graphene oxide (GO) can be employed [18] . GO has been found to have applications in a variety of new applications such as electronic devices, sensors and energy-related techniques due to its interesting properties. The presence of oxygen functionalities causes a decrease of GO conductivity but, on the other hand, it improves GO solubility in aqueous solutions and allows the interaction with a number of chemical entities. Moreover, water solubility is consistent with the higher biological compatibility of GO compared to graphene that needs to be properly supported in order to be able to interact with biological substrates [19, 20] . These peculiar characteristics have been considered promising for the development of a variety of biosensing strategies in which graphene material has been applied as a transducer of biological signals in electrochemical, fluorescence and impedance biosensors [21] [22] [23] [24] .
Here, we report the extension of the GO-based electrochemical approach [21] to two common polymorphic variants of hFMO3 enzyme, E158K and E308G. These two hFMO3 variants were expressed in a recombinant system and immobilised on didodecyldimethylammonium bromide (DDAB)/GO glassy carbon electrodes and their activity tested with three hFMO3 marker drugs: benzydamine, a non-steroidal anti-inflammatory drug that is metabolised to its N-oxide by hFMO3 [15] [16] [17] 21, 25] , tamoxifen, a breast cancer drug with antiestrogenic effect, also Noxygenated by hFMO3 [15] [16] [17] 21, 26, 27] ,and sulindac sulfide, a nonsteroidal antiinflammatory drug [11] that is selectively re-oxidised to sulindac by hFMO3 S-oxygenation [2, 25] .
Materials and methods

Chemicals
All the chemical products were obtained in analytical grade and dissolved in ultrapure deionized water immediately before use: GO (concentration of 4 mg/mL in water) from Graphenea (Spain); DDAB, benzydamine (hydrochloride), benzydamine N-oxide (hydrogen maleate), tamoxifen, sulindac sulfide and sulindac from Sigma-Aldrich (Italy); tamoxifen Noxide from Biozol (Germany).
Site-directed mutants of hFMO3
WT hFMO3 cloning was performed using pJL2 expression vector and XbaI and HindIII restriction enzymes, as formerly reported [2] . E158K and E308G polymorphic variants were obtained using QuikChange Site-Directed Mutagenesis Kit (Stratagene, Italy). The primers used were constructed as follows with the mutation site highlighted in bold: DNA sequencing of the clone confirmed the presence of the mutation in the correct position.
Expression and purification of human FMO3
WT, E158K and E308G hFMO3 proteins were obtained by expression in Escherichia coli (JM109) cells and purification by applying the protocol already optimized for the wild type enzyme [2] . In particular, the proteins were extracted from cells membrane fractions and purified using nickel affinity chromatography. After the purification, proteins purity was checked by visualization in a 10% SDS-polyacrylamide gel stained with Coomassie Blue. hFMO3 enzymes concentration was estimated considering an FAD equimolar content, an extinction coefficient of 11,300 M -1 cm -1 at 450 nm and a molecular weight of 56 kDa [28] .
FTIR spectroscopy
Infrared spectroscopy experiments on hFMO3 polymorphic variants were performed on gold- Afterwards, data analysis and curve fitting were carried out using PeakFit software (SPSS Inc., USA).
Electrode preparation
The preparation of glassy carbon electrodes was obtained as previously described [21] . In particular, 10 µL of 20 mM DDAB solution in chloroform or DDAB plus 5 µL of GO water dispersion (1 mg/mL) were deposited on the electrode surface and left 10 minutes at 25°C to permit evaporation of the solvent. The electrodes were further modified by adding 5 µL of purified WT hFMO3 solution (145 µM), E158K hFMO3 solution (121 µM) or E308G hFMO3 solution (43 µM) and kept at least 2 hours at 4°C for before any other experimental procedure.
Cyclic voltammetry and chronoamperometry
All electrochemistry procedures were developed on Autolab PGSTAT12 potentiostat controlled by GPES3 software (Ecochemie, The Netherlands). Electrochemical setup was composed by an electrolysis glass cell equipped with a platinum wire counter electrode, Ag/AgCl (3 M NaCl) reference electrode and 3 mm diameter glassy carbon working electrode (BASi, USA). Electrolysis buffer was 50 mM phosphate buffer pH 7.4 with the addition of 100 mM KCl as supporting electrolyte.
hFMO3 polymorphic variants were studied electrochemically by cyclic voltammetry, in presence and in absence of GO, at 25°C in absence of oxygen using a glovebox (Belle Technologies, UK). Cyclic voltammetry was performed using a potential range between +100
and -750 mV at increasing scan rates.
Electrocatalysis experiments on newly prepared hFMO3/DDAB/GO glassy carbon electrodes were carried out using chronoamperometry at an applied potential of -650 mV for 15 min in presence of rising concentrations of benzydamine, tamoxifen or sulindac sulphide substrates.
In order to choose the correct electrocatalysis duration, a series of experiments was performed in the presence of saturating concentration of benzydamine (300 µM) and the amount of Substrate permeation throughout enzyme layer and minimisation of mass transport control at the electrode was achieved by using glassy carbon rotating disk electrodes controlled by a BASi RDE-2 rotator system (BASi, USA) set at 200 rpm rotation speed. Electrocatalysis samples obtained by chronoamperometry were immediately subjected to HPLC separation and quantification. The quantification of metabolites was achieved using calibration curves obtained by the injection of standard solutions for benzydamine N-oxide, tamoxifen N-oxide and sulindac.
HPLC
Electrocatalysis products were detected and quantified by injecting samples in an HPLC system coupled with a diode array UV detector (Agilent-1200, Agilent technologies, USA) with a 4.6
x 150 mm, 5 µm Eclipse XDB-C18 column as stationary phase, as previously reported [17] .
Benzydamine and benzydamine N-oxide were separated using the following procedure: 0-10 minutes, gradient elution of acetonitrile from 20% to 40% and 50 mM KH 2 PO 4 from 80% to 60%; 10-12 minutes, isocratic elution of 40% acetonitrile and 60% 50 mM KH 2 PO 4 ; 12 minutes-end of the run, gradient elution of acetonitrile from 40% to 60% and 50 mM KH 2 PO 4 from 60% to 40%. The flow rate was 1 mL/min and detection wavelength was 308 nm.
Retention times were 17.5 min for benzydamine N-oxide and 20 min and benzydamine.
Tamoxifen and tamoxifen N-oxide were eluted isocratically using a mobile phase composed by 82% methanol and 18% triethylamine (1%), at a flow rate of 0.8 mL/min. Detection wavelength was 278 nm. Retention times were 7 min for tamoxifen N-oxide and 15 min and tamoxifen.
Sulindac sulfide and sulindac were separated using using the following procedure: 0-6 minutes, isocratic elution of 30% acetonitrile and 70% 50 mM KH 2 PO 4 , flow rate 1.4 mL/min; 6-12 minutes, gradient elution of acetonitrile to 45% and 50 mM KH 2 PO 4 to 55%, and to flow rate 1.6 mL/min; 8 minutes-end of the run, isocratic elution of 45% acetonitrile and 55% 50 mM KH 2 PO 4 , flow rate 1.6 mL/min. Detection wavelength was set at 360 nm. Retention times were 5.2 min and 16 min for sulindac sulfide and sulindac, respectively.
Results and Discussion
FTIR spectroscopy
The effect of hFMO3 polymorphism on the secondary structure of E158K and E308G variants in the presence of GO was studied by FTIR spectroscopy. There is currently no published crystal structure of the wild type hFMO3 protein but using FTIR spectroscopy one can compare the wild type secondary structure content with the two polymorphic variants. As previously reported for the WT protein [21] , also here no effect on the IR spectral features was observed for the two hFMO3 polymorphic variants due to the presence of GO (data not shown). Figure 1A shows the spectrum obtained for the WT hFMO3 enzyme compared to those of E158K and E308G variants. All spectra exhibit the characteristic features of protein IR spectra:
amide I, II and III bands. Amide I band (~1650 cmtransition of peptidic carbonyl group and in minor part of out-of-phase C-N stretching vibration [29] . In this region of the IR spectrum a series of signals rigorously correlated to protein secondary structures can be observed. Amide I band is the result of the merging of these bands and for this reason the deconvolution of amide I, together with the estimation of the contribution of each single signal to the amide I band, can give important details about protein secondary structure composition. Amide II band is detectable at around 1545 cm -1 and is due to the out-of-phase bending of the peptidic N-H bond and the stretching of the peptidic C-N bond.
The peak at 1517 cm -1 is related to the stretching of C-C bond and the bending of C-H bond of side chain tyrosine residues [29] . Amide III band can be observed in the wavenumbers range of IR spectrum between 1200 and 1400 cm -1 . This signal is related to the in-phase combination of the bending of the peptidic N-H and C-N bonds [30] .
"Here Figure 1 "
All in all, the results of infrared spectroscopy do not seem to show major differences related to hFMO3 polymorphism. However, a proper investigation on the secondary structure composition of both E158K and E308G hFMO3 variants was achieved by analysing the composition of the amide I band of both IR spectra in its component bands after identification of their position through the peak deconvolution ( Figures 1B and 1C) . It is well established that the profile of the amide I band of proteins is typical of their secondary structure and that secondary structure composition can be predicted analysing the amide I band component bands by deconvolution.
Amide I components were then assigned to the related protein secondary structure [29, 30] and their involvement to the polymorphic proteins secondary structure composition was calculated in percentage both for E158K and E308G hFMO3. Table 1 compares the secondary structure components of hFMO3 polymorphic variants with those previously measured for WT protein [21] . The results obtained are very similar for what concerns peak positions, but the percentages of the different components show some differences. In particular, variant E308G seems to be structurally more similar to the WT, with only some small differences in the turns and unordered loops, while the E158K shows more significant differences also in the alpha helices and beta sheets. Based on these results, the E158K mutation seems to show slight structural differences compared to WT protein. However, since there is no published crystal structure for the WT protein as mentioned above, it is difficult to unequivocally confirm these observed differences.
"Here Table 1 "
Direct electrochemistry of hFMO3 polymorphic variants
Cyclic voltammetry of hFMO3 polymorphic variants was performed both on DDAB and on DDAB/GO glassy carbon electrodes. Figure 2 shows the different steps involved in the preparation of the immobilised enzyme(s) on GO modified glassy carbon electrodes. hFMO3, in the presence and in the absence of GO. As already shown for the wild type protein [21] , reduction/oxidation process was found electrochemically reversible for both hFMO3
variants. On control electrodes prepared without enzymes, no voltammetric peaks were observed (data not shown). Peak currents and scan rate values up to 120 mV s -1 were found linearly correlated (Figure 3, insets) . Based on the postulated of Laviron's theory [31] , this property is typical of electroactive species restricted in thin layer that are not controlled by passive diffusion events. A significant increase in the redox peak currents of the polymorphic variants was observed in presence of GO (P < 0.001) as also previously noted for WT protein [21] . Since no voltammetric peaks were detected on control electrodes in the absence of protein, the increase in voltammetric peak current values can be ascribed to GO improvement on electron transfer properties rather than to an increase of the mass on the electrode. Redox features of both E158K and E308G hFMO3/DDAB/GO electrodes are summarised in Table 2 and compared to those of free FAD and WT protein.
"Here Figure 3 "
As can be seen, the mean potential (E 1/2 ) of both polymorphic variants was shifted to more positive values compared to free FAD and WT enzyme. No statistical differences were observed between peak-to-peak separation values, meaning that hFMO3 polymorphic variants, like WT protein, are characterised by a quasi-reversible electron transfer redox system. "Here Table 2 "
The calculation of apparent surface coverage (G) was obtained by plotting the peak current versus the scan rate through Faraday's law for both hFMO3 variants. Electron transfer rate constant (k s ) was determined for both variants by plotting cathodic and anodic peak potentials versus the logarithm of the scan rate using Laviron's equations [31] . For these calculations, cyclic voltammetry experiments were performed in order to investigate irreversible electrochemistry of hFMO3 proteins using a scan rate ranging from 10 to 22 V s -1 . The k s values were estimated by measuring the intercept of E plot versus the natural logarithm of scan rate ( Figure S3 ) and were calculated to be 64.4 ± 8.5 s -1 for E158K hFMO3/DDAB/GO and 51.0 ± 8.3 s -1 for E308G hFMO3/DDAB/GO. A statistical improvement in the electron transfer rate expressed by the k s value was found when comparing E158K variant to WT protein, while no significant differences were found between E308G variant and WT hFMO3.
Electrocatalytic activity of hFMO3 polymorphic variants
Catalytic activity of hFMO3 polymorphic variants on GO electrodes was examined and compared to WT protein using benzydamine and tamoxifen by performing chronoamperometry on glassy carbon rotating disk electrodes ( Figure 4A Table 3 . For benzydamine electrocatalysis, K M values were 77.0 ± 9.3 µM and 52.2 ± 6.3 µM for E158K
and E308G variants, respectively. When comparing these values with WT protein, a significant difference was found for E158K but not for E308G. The calculated k cat values for benzydamine electrocatalysis were 35.5 ± 1.6 min -1 and 54.4 ± 2.1 min -1 for E158K and E308G variants, respectively. The turnover number values of both variants were statistically lower than those of WT. In both cases, E158K and E308G mutations had a negative effect on benzydamine catalysis, but only in the case of E158K variant this corresponds to a reduction in substrate affinity.
For tamoxifen electrocatalysis, K M values were 47.1 ± 9.0 µM and 4.6 ± 0.5 µM, respectively for E158K and E308G hFMO3 (Table 3) . Again, while no differences were found between K M values of WT and E308G variant for tamoxifen, a significant decrease in the enzyme affinity for tamoxifen was detected in the case of E158K variant. The calculated k cat values for tamoxifen electrocatalysis were 12.1 ± 0.7 min -1 and 20.3 ± 0.5 min -1 for E158K and E308G
variants, respectively. In this case, E158K showed lower catalytic activity towards tamoxifen while E308G had higher activity when compared to WT hFMO3.
For sulindac sulfide electrocatalysis, K M values were 45.2 ± 7.0 µM, 53.2 ± 7.8 µM and 41.0 ± 9.9 µM, respectively for WT, E158K and E308G hFMO3. As can be seen, there were no significant differences when comparing these values and therefore it can be concluded that the single mutations have no effect on the affinity of resulting enzymes for this drug. The calculated k cat values for sulindac sulfide electrocatalysis were 64.9 ± 2.7 min -1 , 80.3 ± 3.3 min -1 and 61.5 ± 3.9 min -1 for WT, E158K and E308G variants, respectively.E158K variant showed a slightly higher catalytic activity with respect to WT, highlighting the fact that E158K mutation could be unfavourable for N-oxygenation activity of hFMO3 but favourable forits Soxygenation activity. As for E308G mutation, no differences were observed for either the Soxidation activity of this variant or the N-oxidation activity with benzydamine compared to the WT. However, this mutation was relevant fortamoxifen metabolism where it demonstrated the highest k cat .
In order to better visualize the electrocatalysis data of the comparison between the WT hFMO3 and its two variants, the catalytic efficiency (k cat /K M ratio) for each enzyme was calculated and the data are summarised in the Table 3 together with K M and k cat values. "Here Table 3 "
As can be seen in the Table 3 The results were also compared with previously published data on the activity of hFMO3 polymorphic variants. A general decrease in hFMO3 activity has been associated both to E158K and E308G allelic variants [32] . Regarding benzydamine N-oxygenation, an impairment of the enzyme activity was found for E158K variant [33, 34] using recombinant protein expressed in E. coli or in baculovirus infected insect cells microsomes. A further impairment was also observed for E158K-E308G double mutant of hFMO3. In none of the cases this impairment corresponded to a decreased affinity for benzydamine. In the case of sulindac sulfide S-oxygenation, E158K and E308G polymorphisms have also been associated with a decreased hFMO3 activity [34, 35] . Moreover, in vivo studies demonstrated that E158K
and E308G polymorphisms occur more frequently in familial adenomatous polyposis patients responding well to sulindac sulfide [36, 37] . As for tamoxifen N-oxygenation, Krueger and colleagues showed an improvement of both enzyme affinity and activity due to E158K mutation using a recombinant system in baculovirus [27] .
In general, there are only a handful of published data on the activity of hFMO3 polymorphic variants and in some cases as mentioned above, these data are not consistent. Our data support the overall decrease in the N-oxygenation activity of the E158K polymorphic variant similar to the published literature data however, we do not observe any differences with sulindac sulfide. Furthermore, for tamoxifen metabolism only data on the E158K polymorphism has been published but we see the same improvement also in the activity of E308G [27] .
Conclusions
The effect of polymorphism on enzyme turnover efficiency in the presence of drugs is an essential issue to be tackled for human hepatic drug metabolising enzymesincluding hFMO3.
The different polymorphic variants of hFMO3 have been frequently associated with the lower activity of this enzyme. Two common polymorphic variants of hFMO3, E158K and E308G, were expressed in bacteria and immobilised on glassy carbon electrodes in the presence of GO.
Due to the attractive electrochemical and mechanical properties of GO, this nanomaterial has been extensively used as a high performance electrochemical transducer. The presence of GO in the electrochemical set up enhanced the signal of both E158K and E308G hFMO3 variants in cyclic voltammetry. For both polymorphic variants, a positive shift in the redox potential was observed when compared to the WT protein. The catalytic properties of E158K and E308G polymorphic variants were measured using three known substrates of hFMO3; benzydamine, tamoxifen and sulindac sulfide and, the results were compared to those obtained for the WT enzyme. In particular, E158K variant showed a significant impairment in its N-oxygenation activity, both in the presence of benzydamine and tamoxifen, whereas E308G variant had an increased N-oxygenation activity with tamoxifen. Moreover, none of the two variants showed any differences in catalytic efficiency when S-oxygenation of sulindac sulfide was tested. The possible involvement of GO in the metabolic pattern observed for hFMO3 polymorphic variants with respect to the WT protein was mainly excluded due to experimental data related to the preservation of both the correct protein folding (by FTIR) and the measured redox potentials of WT and polymorphic variants of hFMO3. However, unequivocal exclusion of the GO effect needs further investigations.
Finally in this work, the unique features of GO were applied to the elucidation of the role of by WT (black circles), E158K (black squares) and E308G (white triangles) hFMO3/DDAB/GO glassy carbon electrodes: plot of reaction velocity versus substrate concentration fitted to
